FSLR enters its Q2 print with a fresh analyst upgrade pulling against a stock that has shed 18% over the past month — and short sellers quietly rebuilding positions into the slide.
The most striking development this week is the analyst action. Deutsche Bank upgraded First Solar to Buy on July 7, lifting its target from $245 to $272. That move followed Wells Fargo raising its Overweight target from $255 to $320 just a day earlier. Both firms are acting after a steep drawdown, with the stock now at $227.72 — well below the Street's mean target of $250.71 and far below Wells Fargo's $320. The consensus sits at Buy, with 13 buy-rated analysts versus 11 holds. Bernstein's June initiation at Underperform with a $217 target is the clearest bearish outlier, sitting just below current levels and implying the recent selloff has already priced in the upside the bulls are chasing. UBS and Mizuho have both lifted targets in recent weeks, suggesting the broader direction of travel is still constructive — but the 18% one-month decline makes clear the market is not yet convinced.
Short positioning tells a story of modest but persistent rebuilding. Short interest has climbed to 8.3% of the free float — up roughly 3% on the week and ticking back toward levels last seen in early June after a brief dip to the 8.2% area in mid-month. The absolute level is meaningful without being extreme. Critically, the borrow market is loose: availability is running at over 1,000% of short interest, meaning shares are plentiful for anyone wanting to add to a short position. Cost to borrow is just 0.42%, down 14% on the week, so there is no squeeze pressure whatsoever. Options positioning is mildly more cautious than usual — the put/call ratio is at 0.58, slightly above its 20-day average of 0.56, about 1.3 standard deviations elevated — but that is a modest tilt, not a defensive panic. The positioning picture is one of controlled skepticism: bears are adding gradually, the lending market accommodates them easily, and options traders are only lightly hedging.
The bull and bear cases are genuinely divergent heading into the July 28 print. Bulls point to CdTe pricing strength potentially lifting 2026 and 2027 revenues roughly 2% above consensus, with Mizuho's $300 target and UBS's $330 reflecting confidence in gross margin recovery toward 20% in 2026. Bears worry about module underperformance, declining backlog coverage, and the risk that management lowers full-year guidance — a scenario roughly 35% of investors reportedly anticipate. The EV/EBITDA multiple has compressed to about 8.4x over the past 30 days, while the P/E has drifted down to around 12x, giving the value-oriented case some grounding. Factor scores add nuance: EPS momentum over both 30 and 90 days ranks poorly (44th and 27th percentile respectively), while EPS surprise scores at the 64th percentile — suggesting the company tends to beat but estimates have been trending in the wrong direction.
Insider activity reinforces the cautious tone. CEO Mark Widmar sold roughly $1.3 million worth of shares in late May at prices between $267 and $277 — well above the current $227.72. The HR Director sold nearly $3 million at $275 around the same time. Net insider selling over the past 90 days totals approximately $6.7 million. None of these were large relative to the company's size, and the trades were spread across multiple tranches suggesting planned disposals, but the direction is uniformly one-way. BlackRock recently added over 1.2 million shares, bringing its stake to 12.9% of shares outstanding — a meaningful institutional vote of confidence that offsets some of the insider signal.
Q2 earnings results from the most recent event show the stock moved just 1.6% the next day, gaining 4.3% over the five days following. The prior event in April produced an 11% one-day jump and a 12.6% five-day move. Those two data points suggest outcomes have been wide-ranging, making the direction of any guidance commentary the key variable to watch on July 28.
With two high-profile upgrades arriving into a deeply sold-off stock, the week ahead shapes up as a test of whether analyst conviction can stabilize a name where shorts are rebuilding, insiders have been selling, and the next earnings catalyst is just three weeks away.
See the live data behind this article on ORTEX.
Open FSLR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
